["Double-blind" clinical study of a non-steroid anti-inflammatory drug: glucametacine].
A double blind clinical study has been carried out with two non-steroid anti-inflammatory drugs, glucametacine and phenylbutazone in 40 patients suffering from inflammatory and degenerative type arthrorheumopathies, selected and randomised into two groups. Examination of results shows the greater effectiveness of glucametacine (78%)over phenylbutazone (60%). Glucametacine was also statistically (p < 0,05) better from the tolerance point of view.